BioCentury | Jun 23, 2020
Product Development

June 22 Quick Takes: Invitae acquiring ArcherDX; plus lymphoma approval for Karyopharm, Merck, Nabriva, Myovant, Assembly-AbbVie, Genentech and more

ArcherDX picks deal with Invitae over IPO  Genetic testing company Invitae (NYSE:NVTA) is acquiring ArcherDX Inc., adding a cancer diagnostics platform to its precision oncology business. ArcherDX’s shareholders will receive $325 million in cash plus...
BioCentury | May 30, 2020
Product Development

ASCO data bring new markets within reach for two AstraZeneca therapies

AstraZeneca stole the show at ASCO on Friday with data that should help propel its top-grossing cancer drug and one of its newest market entrants into broadly expanded patient populations, as long as physicians adopt...
BioCentury | May 30, 2020
Product Development

May 29 ASCO Quick Takes: Investors sour on Arvinas’ targeted degraders; plus MacroGenics, Karyopharm, Blueprint

Targeted degrader company Arvinas takes hit on updated proof of concept data  Arvinas Inc. (NASDAQ:ARVN) shed nearly $500 million in market cap Friday after updated Phase I/II data showed no new responses among 12 additional...
BioCentury | May 15, 2020
Product Development

May 14 ASCO Quick Takes: Alphamab rises on responses for pair of bispecific mAbs; plus ImmunoGen and CytomX

Alphamab bispecifics against checkpoints, pair of HER2 sites  In an abstract released ahead of this month’s American Society of Clinical Oncology virtual meeting, Alphamab Oncology Ltd. (HKEX:9966) reported data from a Phase I trial showing...
BioCentury | May 15, 2020
Product Development

TIGIT emerges as a standout next generation checkpoint target at ASCO

Drugmakers have been searching for the next checkpoint inhibitor ever since CTLA-4 and PD-1 triggered the immuno-oncology movement roughly five years ago; however, most have disappointed in the clinic. New data presented at the 2020...
BioCentury | May 13, 2020
Product Development

May 12 Quick Takes: Skyhawk, Merck expand deal; plus Sanofi’s Sarclisa and clinical updates drive gains for Gamida, CymaBay

Autoimmune, metabolic diseases added to Skyhawk-Merck deal  Skyhawk Therapeutics Inc. expanded a collaboration with Merck & Co. Inc. (NYSE:MRK) to discover and develop small molecules that modulate RNA splicing for autoimmune and metabolic diseases; the...
BioCentury | May 6, 2020
Product Development

May 5 Quick Takes: Data propel Adverum, TG, Akebia stocks; plus Tolmar, SRI-Exscientia, Sino-GeoVax

TG’s combo meets Phase III leukemia endpoint  TG Therapeutics Inc. (NASDAQ:TGTX) climbed $4.23 (34%) to $16.69 on Tuesday after CD20 inhibitor ublituximab plus PI3Kδ inhibitor umbralisib met the primary endpoint of progression-free survival (PFS) in...
BioCentury | Apr 28, 2020
Product Development

Blueprint stumbles in GIST race, clearing path for Deciphera

A Phase III miss for Blueprint’s Ayvakit avapritinib in third- and fourth-line GIST likely means the biotech won’t see its NDA approved in the indication, positioning Deciphera to claim a larger share of late-stage settings....
BioCentury | Apr 20, 2020
Product Development

Opdivo-Cabometyx combo improves PFS by 49%, OS by 40% in first-line RCC

Exelixis jumped $4.14 (21%) to $23.58 on Monday, pushing its valuation above $7 billion, after the biotech and partners Bristol Myers Squibb and Ipsen said the combination of Opdivo nivolumab plus Cabometyx cabozantinib generated positive...
BioCentury | Apr 6, 2020
Product Development

Immunomedics doubles in value on Phase III update for TNBC therapy ahead of June PDUFA; names Semerjian CEO

After halting a Phase III trial early due to efficacy in the difficult setting of triple-negative breast cancer, Immunomedics named a new, commercially-experienced CEO to help the biotech transition into a commercial launch phase. Immunomedics...
Items per page:
1 - 10 of 5285